ACE and heart failure: The resulting substantial burden on health care systems and the associated costs are a consequence of ageing populations and improvements in the medical management of heart failure with the use of therapies such as beta-blockers, ACE inhibitors, aldosterone inhibitors and device therapies that prolong survival after ischaemic heart damage or heart failure related to hypertension and valvular heart disease.